Choroidal neovascularization
MONDO:0810000An eye disorder described by the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the sub–retinal pigment epithelium (sub-RPE) or subretinal space. Choroidal neovascularization (CNV) is a major cause of visual loss.
21 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsBroader categories
-
Timing eye injections: could 3, 7, or 14 days before surgery matter?
Disease control CompletedThis trial tests whether giving anti-VEGF injections 3, 7, or 14 days before surgery makes a difference for people with proliferative diabetic retinopathy, a complication of diabetes that causes abnormal blood vessels in the eye. Participants are randomly assigned to one of three…
Sponsor: Jie Li • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug faricimab takes on leading cause of blindness in nearsighted people
Disease control CompletedThis study tested a drug called faricimab (VABYSMO®) against an existing treatment (ranibizumab) for people with vision loss caused by abnormal blood vessels growing in the back of the eye due to severe nearsightedness. The trial involved 280 participants who received either fari…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
Disease control CompletedThis study tests whether switching to a higher dose (8mg) of aflibercept can help people with wet age-related macular degeneration (AMD) who have not responded well to standard treatments like faricimab or the usual 2mg dose of aflibercept. Participants receive up to three inject…
Phase 4 • Sponsor: Kim's Eye Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New syringe design makes eye injection easier for doctors
Disease control CompletedThis study tested whether a pre-filled syringe of the medicine SB11 (a biosimilar to ranibizumab) is easy for eye doctors to use. Thirty adults with wet age-related macular degeneration, macular edema from retinal vein occlusion, or myopic choroidal neovascularization received on…
Phase 2 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Eye drug dosing showdown: can fewer injections still control wet AMD?
Disease control CompletedThis study compared two different dosing schedules of brolucizumab (Beovu) in 52 people with wet age-related macular degeneration (AMD) who had not responded well to previous treatment. Participants received the drug as an eye injection either on a fixed schedule or with adjustme…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC